Inhaled Anti-Infectives Market
Industry: Healthcare
Format: PPT*, PDF, EXCEL
Delivery Timelines: Contact Sales
Report Type: Ongoing
Report ID: PMRREP32351
The Inhaled drugs are an essential therapy for the treatment of chronic lung disease, owing to the rapid supply of the medicine to the airways. Inhaled corticosteroids help to prevent asthma attacks and improve lung function. Dry powder inhalers, Metered-dose inhalers (MDIs), soft mist inhalers and nebulizers are currently offered in the market with other medicines for the treatment of respiratory diseases. The major factor that will boost the market are rising R&D expenditure for the enhancement of advanced therapies and developed drugs in the market and development of methods for early diagnosis and treatment along with reduced undiagnosed cases. The major use of the inhaled antibiotics is to get maximum drug delivery at the target site of infection such as the airways and avoid the possible systemic side effects.
The key trends are rising incidences of respiratory diseases globally, especially in the last decade. Asthma is a major health concern affecting a large number of people across the globe. The one of the most life-threatening disease in lung disease is chronic obstructive pulmonary disease (COPD) that is accountable for early mortality and high death rates. Chronic Obstructive Pulmonary Disease (COPD) are emphysema and chronic bronchitis. As per the World Health Organization, at present there are 4.3% patients of asthma worldwide.
As per the Forum of International Respiratory Societies (FIRS), the patients of COPD are more than 200 million globally and is supposedly to be the third primary cause of death worldwide by 2030. As per CDC, number of visits to emergency departments with pneumonia as the primary diagnosis was 3.4 million in U.S. in 2020. Hence the increasing lung diseases and thereby, increasing the need for inhaled antibiotics therapy is expected to propel the growth.
There is increasing occurrence of respiratory diseases like chronic obstructive pulmonary diseases (COPD), asthma and bronchitis which is anticipated to boost the market growth over the forecast period. As per the World Health Organization Report of May 2020, asthma is the most common chronic disease among children worldwide and around 339 million people live with asthma.
Moreover, according to the World Health organization 2020 report, around 200 million cases of chronic obstructive pulmonary diseases are found globally and approximately 3.17 million deaths are caused by chronic obstructive pulmonary diseases. Similarly, according to the same source, almost 90% of COPD deaths take place in low and emerging countries.
Key players operating in the global market are focusing on novel product launches, in order to expand their product portfolio and increase their presence in the global market.
For instance, in 2019, Polyphor, a Swiss specialty pharmaceutical company, Polyphor offered a new in-vivo efficacy and tolerability data for a potential inhaled administration of its lead antibiotic murepavadin at the European Cystic Fibrosis Conference.
Less awareness among the general population regarding treatment options available for lung infections is expected to hinder global inhaled anti-infectives market growth in the coming decade. Moreover, the side-effects related to the drug inhalation and unavailability of single effective inhaler is expected to hinder the market growth. The most commonly observed side-effects reported by the patients after administration of aerosolized antibiotics are coughing, wheezing, haemoptysis with substantial difference by antibiotic. The initial preparation of inhaled tobramycin that was studied involved a preservative that caused irritation in the airway.
In addition, resistance that is gained by microorganisms in historically is one of the main restraint that limits the present market of anti-infectives to grow. Furthermore, the great competition existing in the market owing to the vast expansion of this sector is showing a restraint for growth opportunities in the market.
Major companies involved in the production and novel R&D activities for the development of Inhaled anti-infectives involve
Key market players adopt product launches and approval strategies to expand their presence and product portfolio globally and satisfy the growing demand. Funding and assistance that is provided by governmental as well as non-governmental groups such as WHO will boost the market growth. Furthermore, the increase in advanced research activities for the discovery and developments of novel technological advancements would be the major benefit for global players. Also, the Rising reimbursements in almost globally is also growing the market.
The development of different antibiotics by collaborating with different companies is one of the main strategies for market players.
For instance, in July 2019, The Company Such As Pfizer has launched an international research consortium to discover and develop new TB antibiotics in collaboration with eight biotechnology partners and European academic.
Rising investment towards research and development activities in regions like North America and Europe is expected to create a large number of opportunities for global Inhaled anti-infectives market growth. The shift of lifestyle patterns towards unhealthy lifestyle is expected to increase patient suffering from benign prostate hyperplasia creating large customer based for global Inhaled anti-infectives market.
The increasing number of domestic players in countries like India will lead to a rise in production capacity and growth for global Inhaled anti-infectives market. The emergence of online pharmacies and increasing adoption of e-commerce activities into the global Inhaled anti-infectives market is a key opportunity for market expansion and growth. Increasing number of infectious disorders like COVID 19, influenza and other will rise the number of cases for cytokine storm resulting into increasing demand for Inhaled anti-infectives market.
The global inhaled antibiotics therapy market is divided into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
North America is leading share of the global Inhaled antibiotics therapy market in 2020, followed by Europe. There has been a steady rise in the demand for drug discovery, and a surge in investments toward the development of these drugs. Also, increase in the demand for more quick as well as targeted therapy will aid in quick treatment which will boost the global Inhaled antibiotics therapy market. Recent FDA approvals for inhaled antibiotics indicate the increasing demand among both, public as well as private sectors, also the manufacturers' concentrate on this rising demand.
Developing countries like China and India are observing gradual adoption of novel products, increase in healthcare expenditure, and changing aspects in the in-vitro diagnosis business. This is leading factor in rising adoption of the advanced technologies within the hospitals laboratories.
The rising occurrence of pneumonia, asthma, with rise in the addiction to smoking, and also increase in environmental pollution in China and India is expected to boost the market in the near future. As per an article that was published in the Lung India journal, it was assessed that in 15-20 million asthma patients, minimum one in every 10 asthma patients, worldwide, is from India. Additionally, rise in concentration on lung disease treatment and rising awareness among people about managing asthma boosts the market in the region.
The pandemic is throwing a huge adverse impact on the Inhaled antibiotics therapy market. Biopharmaceutical and healthcare industries as a whole were hit by this pandemic challenge in 2020. The supply chain interruption and economic impact of the pandemic on the small, and medium-sized enterprises also adversely affected the Inhaled antibiotics therapy market growth. As the importing was halted, this has adversely affected the finances of the majority of pharmaceutical companies. The shortage of manpower due to COVID19 pandemic also hamper in research and development as well as commercial production of biologics all over the world which is also the major factor have a huge impact on the Inhaled antibiotics therapy market growth in 2020.
The health crisis worldwide has shown an extraordinary influence on businesses across all the industries. Though, this is considered to be a short-term effect, but, the growing assistance from governments and key players can help in the fight against this coronavirus pandemic. Moreover, it is observed that some industries that are struggling and some are flourishing. Globally, every segment is predicted to be influenced by the pandemic. In the light of COVID-19 pandemic, there is a greater demand for various types of treatment of respiratory diseases during the COVID-19 treatment. The rising demand for post COVID-19 monitoring and treatment has led to rise in the demand for various antibiotics. These factors along with the need for rapid treatment will ultimately rise the need of these drugs and drive the global Inhaled antibiotics therapy market.
NOTE - All statements of fact, opinion, or analysis expressed in reports are those of the respective analysts. They do not necessarily reflect formal positions or views of the company.
To know more about delivery timeline for this report Contact Sales
